ABCC2 p.Cys363Ala
| Predicted by SNAP2: | A: N (66%), D: D (66%), E: D (66%), F: N (82%), G: D (53%), H: D (63%), I: N (82%), K: D (71%), L: N (82%), M: D (59%), N: D (59%), P: D (66%), Q: D (66%), R: D (71%), S: N (57%), T: N (53%), V: N (78%), W: N (57%), Y: N (93%), |
| Predicted by PROVEAN: | A: N, D: N, E: N, F: N, G: N, H: N, I: N, K: N, L: N, M: N, N: N, P: N, Q: N, R: N, S: N, T: N, V: N, W: N, Y: N, |
[switch to compact view]
Comments [show]
None has been submitted yet.
[hide] Transporters and their impact on drug disposition. Ann Pharmacother. 2005 Jun;39(6):1097-108. Epub 2005 May 10. Beringer PM, Slaughter RL
Transporters and their impact on drug disposition.
Ann Pharmacother. 2005 Jun;39(6):1097-108. Epub 2005 May 10., [PMID:15886292]
Abstract [show]
OBJECTIVE: To review the recent advances in knowledge about human transporters and their effect on drug disposition. DATA SOURCES: A MEDLINE search (1996-March 2005) was performed to identify pertinent literature on human transporters and their impact on drug disposition. Additional articles were identified from a manual search of the references of retrieved articles. STUDY SELECTION AND DATA EXTRACTION: Based on the identified studies, data were extracted on the impact of transporters on drug absorption, distribution, and elimination. DATA SYNTHESIS: The pharmacokinetic disposition of drugs is known to be influenced by metabolic enzymes, kidney function, and transporters. Recent research on human transporters has greatly advanced our understanding of their diversity and importance in drug disposition. In particular, members of the multidrug resistance family of transporters (MDR, MRP) are present in organs and tissues throughout the body and are known to significantly affect the absorption, distribution, and elimination of commonly prescribed drugs. A growing number of studies now demonstrate that alterations in transporter function as a result of drug interactions or genetic polymorphisms may explain a significant portion of the variability in treatment response for certain drugs. CONCLUSIONS: Human transporters contribute significantly to the pharmacokinetic disposition of drugs. Knowledge of substrates, inducers, and inhibitors of these transporters is necessary to ensure optimal patient outcomes.
Comments [show]
None has been submitted yet.
No. Sentence Comment
50 and consists of 14 exons.25,26 As with MDR1, polymorphisms with SLCO1B1 are common, with at least 23 single nucleotide polymorphisms and 17 haplotypes identified.27,33 Single nucleotide polymorphisms that occur at a high frequency are e4/A388G, C363A, e5/T521C, A2000G, and G1463C. Five haplotypes are common (OATP-C*1a, OATP-C*1b, OATP-C*5, OATP-C*9, OATP-C*15), with altered protein function occurring with all except OATP-C*1a.
X
ABCC2 p.Cys363Ala 15886292:50:245
status: NEW172 The frequency of the e26/3435C allele and the mh7 haplotype occurs more frequently in African and African Americans than other populations.62,65 As with MDR1, polymorphisms with SLCO1B1 are common, with at least 23 single nucleotide polymorphisms and 17 haplotypes identified.26,66 Single nucleotide polymorphisms that occur at a high frequency are e4/A388G, C363A, e5/T521C, A2000G, and G1463C. Five haplotypes are common (OATP-C*1a, OATP-C*1b, OATP-C*5, OATP-C*9, OATP-C*15), with altered protein function occurring with all haplotypes except OATP-C*1a.
X
ABCC2 p.Cys363Ala 15886292:172:359
status: NEW